The current position of surgical lung biopsy in the diagnosis of idiopathic pulmonary fibrosis

Respiratory Research

Riitta Kaarteenaho¹ 

[1] Unit of Medicine and Clinical Research, Pulmonary Division, University of Eastern Finland, PO Box 1777, Kuopio, 70211, Finland

关键词: Video-assisted thoracoscopy;    Usual interstitial pneumonia;    Open lung biopsy;    Non-specific interstitial pneumonia;    Complication;    Fibroblast focus;   

Others  :  794757
DOI  :  10.1186/1465-9921-14-43

 received in 2013-03-01, accepted in 2013-04-10,  发布年份 2013

【 摘 要 】

A new international statement defines usual interstitial pneumonia (UIP) which is a histological and radiological form of idiopathic pulmonary fibrosis (IPF) more precisely than previously. In the diagnosis of IPF, either in high resolution computed tomography (HRCT) a UIP pattern must be present or alternatively specific combinations of HRCT and surgical lung biopsy findings can be accepted. In about two third of the cases IPF can be diagnosed by clinical and radiological criteria. Thus surgical lung biopsy is needed in about one third of cases to achieve the ultimate diagnosis, which requires multidisciplinary cooperation. In large clinical trials conducted during the last decade, lung biopsy was performed in about 30–60% of the cases. The most serious complication of lung biopsy is mortality within 30 days after the procedure, with a frequency of about 3–4% reported in most studies. Because of the histological variability, surgical lung biopsy should be taken from a minimum of two lobes. The number of fibroblast foci in surgical lung biopsy has been shown to correlate with survival in several studies.

【 授权许可】

   
2013 Kaarteenaho; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Muller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schunemann HJ: An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183:788-824.
• [2]Fishbein MC: Diagnosis: to biopsy or not to biopsy: assessing the role of surgical lung biopsy in the diagnosis of idiopathic pulmonary fibrosis. Chest 2005, 128:520S-525S.
• [3]Glaspole IN, Wells AU, du Bois RM: Lung biopsy in diffuse parenchymal lung disease. Monaldi Arch Chest Dis 2001, 56:225-232.
• [4]American Thoracic Society: Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000, 161:646-664.
• [5]Flaherty KR, King TE Jr, Raghu G, Lynch JP III, Colby TV, Travis WD, Gross BH, Kazerooni EA, Toews GB, Long Q, Murray S, Lama VN, Gay SE, Martinez FJ: Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med 2004, 170:904-910.
• [6]Raghu G, Mageto YN, Lockhart D, Schmidt RA, Wood DE, Godwin JD: The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: a prospective study. Chest 1999, 116:1168-1174.
• [7]Flaherty KR, Thwaite EL, Kazerooni EA, Gross BH, Toews GB, Colby TV, Travis WD, Mumford JA, Murray S, Flint A, Lynch JP III, Martinez FJ: Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax 2003, 58:143-148.
• [8]Hunninghake GW, Zimmerman MB, Schwartz DA, King TE Jr, Lynch J, Hegele R, Waldron J, Colby T, Muller N, Lynch D, Galvin J, Gross B, Hogg J, Toews G, Helmers R, Cooper JA Jr, Baughman R, Strange C, Millard M: Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001, 164:193-196.
• [9]Lynch DA, Travis WD, Muller NL, Galvin JR, Hansell DM, Grenier PA, King TE Jr: Idiopathic interstitial pneumonias: CT features. Radiology 2005, 236:10-21.
• [10]Lynch DA, Godwin JD, Safrin S, Starko KM, Hormel P, Brown KK, Raghu G, King TE Jr, Bradford WZ, Schwartz DA, Richard WW: High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med 2005, 172:488-493.
• [11]Mink SN, Maycher B: Comparative manifestations and diagnostic accuracy of high-resolution computed tomography in usual interstitial pneumonia and nonspecific interstitial pneumonia. Curr Opin Pulm Med 2012, 18:530-534.
• [12]Silva CI, Muller NL, Hansell DM, Lee KS, Nicholson AG, Wells AU: Nonspecific interstitial pneumonia and idiopathic pulmonary fibrosis: changes in pattern and distribution of disease over time. Radiology 2008, 247:251-259.
• [13]Sverzellati N, Wells AU, Tomassetti S, Desai SR, Copley SJ, Aziz ZA, Zompatori M, Chilosi M, Nicholson AG, Poletti V, Hansell DM: Biopsy-proved idiopathic pulmonary fibrosis: spectrum of nondiagnostic thin-section CT diagnoses. Radiology 2010, 254:957-964.
• [14]Elliot TL, Lynch DA, Newell JD Jr, Cool C, Tuder R, Markopoulou K, Veve R, Brown KK: High-resolution computed tomography features of nonspecific interstitial pneumonia and usual interstitial pneumonia. J Comput Assist Tomogr 2005, 29:339-345.
• [15]MacDonald SL, Rubens MB, Hansell DM, Copley SJ, Desai SR, du Bois RM, Nicholson AG, Colby TV, Wells AU: Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparative appearances at and diagnostic accuracy of thin-section CT. Radiology 2001, 221:600-605.
• [16]Silva CI, Muller NL, Lynch DA, Curran-Everett D, Brown KK, Lee KS, Chung MP, Churg A: Chronic hypersensitivity pneumonitis: differentiation from idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia by using thin-section CT. Radiology 2008, 246:288-297.
• [17]Fernandez Perez ER, Daniels CE, Schroeder DR, St Sauver J, Hartman TE, Bartholmai BJ, Yi ES, Ryu JH: Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 2010, 137:129-137.
• [18]Hodgson U, Laitinen T, Tukiainen P: Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland. Thorax 2002, 57:338-342.
• [19]Karakatsani A, Papakosta D, Rapti A, Antoniou KM, Dimadi M, Markopoulou A, Latsi P, Polychronopoulos V, Birba G, Ch L, Bouros D: Epidemiology of interstitial lung diseases in Greece. Respir Med 2009, 103:1122-1129.
• [20]Thomeer M, Demedts M, Vandeurzen K: Registration of interstitial lung diseases by 20 centres of respiratory medicine in Flanders. Acta Clin Belg 2001, 56:163-172.
• [21]Tinelli C, De Silvestri A, Richeldi L, Oggionni T: The Italian register for diffuse infiltrative lung disorders (RIPID): a four-year report. Sarcoidosis Vasc Diffuse Lung Dis 2005, 22(Suppl 1):S4-S8.
• [22]Xaubet A, Ancochea J, Morell F, Rodriguez-Arias JM, Villena V, Blanquer R, Montero C, Sueiro A, Disdier C, Vendrell M: Report on the incidence of interstitial lung diseases in Spain. Sarcoidosis Vasc Diffuse Lung Dis 2004, 21:64-70.
• [23]Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, Sato A, Kudoh S: Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005, 171:1040-1047.
• [24]Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM: Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011, 377:1760-1769.
• [25]Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A, Takeuchi M, Raghu G, Kudoh S, Nukiwa T: Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010, 35:821-829.
• [26]Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, Nicholson AG, Verbeken EK, Verschakelen J, Flower CD, Capron F, Petruzzelli S, De Vuyst P, van den Bosch JM, Rodriguez-Becerra E, Corvasce G, Lankhorst I, Sardina M, Montanari M: High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005, 353:2229-2242.
• [27]Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, King TE Jr: A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004, 350:125-133.
• [28]Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR: Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med 2010, 181:604-610.
• [29]King TE Jr, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, Stahler G, Leconte I, Roux S, Raghu G: BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008, 177:75-81.
• [30]King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, du Bois RM: Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009, 374:222-228.
• [31]Raghu G, Brown KK, Costabel U, Cottin V, du Bois RM, Lasky JA, Thomeer M, Utz JP, Khandker RK, McDermott L, Fatenejad S: Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008, 178:948-955.
• [32]Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G, Brun M, Gupta A, Juhel N, Kluglich M, du Bois RM: Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011, 365:1079-1087.
• [33]Bensard DD, McIntyre RC Jr, Waring BJ, Simon JS: Comparison of video thoracoscopic lung biopsy to open lung biopsy in the diagnosis of interstitial lung disease. Chest 1993, 103:765-770.
• [34]Ferson PF, Landreneau RJ, Dowling RD, Hazelrigg SR, Ritter P, Nunchuck S, Perrino MK, Bowers CM, Mack MJ, Magee MJ: Comparison of open versus thoracoscopic lung biopsy for diffuse infiltrative pulmonary disease. J Thorac Cardiovasc Surg 1993, 106:194-199.
• [35]Molin LJ, Steinberg JB, Lanza LA: VATS increases costs in patients undergoing lung biopsy for interstitial lung disease. Ann Thorac Surg 1994, 58:1595-1598.
• [36]Rena O, Casadio C, Leo F, Giobbe R, Cianci R, Baldi S, Rapellino M, Maggi G: Videothoracoscopic lung biopsy in the diagnosis of interstitial lung disease. Eur J Cardiothorac Surg 1999, 16:624-627.
• [37]Mouroux J, Clary-Meinesz C, Padovani B, Perrin C, Rotomondo C, Chavaillon JM, Blaive B, Richelme H: Efficacy and safety of videothoracoscopic lung biopsy in the diagnosis of interstitial lung disease. Eur J Cardiothorac Surg 1997, 11:22-26.
• [38]Miller JD, Urschel JD, Cox G, Olak J, Young JE, Kay JM, McDonald E: A randomized, controlled trial comparing thoracoscopy and limited thoracotomy for lung biopsy in interstitial lung disease. Ann Thorac Surg 2000, 70:1647-1650.
• [39]Park JH, Kim DK, Kim DS, Koh Y, Lee SD, Kim WS, Kim WD, Park SI: Mortality and risk factors for surgical lung biopsy in patients with idiopathic interstitial pneumonia. European Journal of Cardio-thoracic Surgery 2007, 31:1115-1119.
• [40]Sigurdsson MI, Isaksson HJ, Gudmundsson G, Gudbjartsson T: Diagnostic surgical lung biopsies for suspected interstitial lung diseases: a retrospective study. Ann Thorac Surg 2009, 88:227-232.
• [41]Fibla JJ, Brunelli A, Cassivi SD, Deschamps C: Aggregate risk score for predicting mortality after surgical biopsy for interstitial lung disease. Interact Cardiovasc Thorac Surg 2012, 15:276-279.
• [42]Kaarteenaho R, Kinnula VL: Diffuse alveolar damage: a common phenomenon in progressive interstitial lung disorders. Pulm Med 2011, 2011:531302.
• [43]Lettieri CJ, Veerappan GR, Helman DL, Mulligan CR, Shorr AF: Outcomes and safety of surgical lung biopsy for interstitial lung disease. Chest 2005, 127:1600-1605.
• [44]Tiitto L, Heiskanen U, Bloigu R, Paakko P, Kinnula V, Kaarteenaho-Wiik R: Thoracoscopic lung biopsy is a safe procedure in diagnosing usual interstitial pneumonia. Chest 2005, 128:2375-2380.
• [45]Utz JP, Ryu JH, Douglas WW, Hartman TE, Tazelaar HD, Myers JL, Allen MS, Schroeder DR: High short-term mortality following lung biopsy for usual interstitial pneumonia. Eur Respir J 2001, 17:175-179.
• [46]Pompeo E, Rogliani P, Cristino B, Schillaci O, Novelli G, Saltini C: Awake thoracoscopic biopsy of interstitial lung disease. Ann Thorac Surg 2013, 95(2):445-52.
• [47]Nicholson AG, Fulford LG, Colby TV, du Bois RM, Hansell DM, Wells AU: The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2002, 166:173-177.
• [48]Aziz ZA, Wells AU, Hansell DM, Bain GA, Copley SJ, Desai SR, Ellis SM, Gleeson FV, Grubnic S, Nicholson AG, Padley SP, Pointon KS, Reynolds JH, Robertson RJ, Rubens MB: HRCT diagnosis of diffuse parenchymal lung disease: inter-observer variation. Thorax 2004, 59:506-511.
• [49]Peckham RM, Shorr AF, Helman DL Jr: Potential limitations of clinical criteria for the diagnosis of idiopathic pulmonary fibrosis/cryptogenic fibrosing alveolitis. Respiration 2004, 71:165-169.
• [50]Thomeer M, Demedts M, Behr J, Buhl R, Costabel U, Flower CD, Verschakelen J, Laurent F, Nicholson AG, Verbeken EK, Capron F, Sardina M, Corvasce G, Lankhorst I: Multidisciplinary interobserver agreement in the diagnosis of idiopathic pulmonary fibrosis. Eur Respir J 2008, 31:585-591.
• [51]Flaherty KR, Travis WD, Colby TV, Toews GB, Kazerooni EA, Gross BH, Jain A, Strawderman RL, Flint A, Lynch JP, Martinez FJ: Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 2001, 164:1722-1727.
• [52]Monaghan H, Wells AU, Colby TV, du Bois RM, Hansell DM, Nicholson AG: Prognostic implications of histologic patterns in multiple surgical lung biopsies from patients with idiopathic interstitial pneumonias. Chest 2004, 125:522-526.
• [53]Travis WD, Hunninghake G, King TE Jr, Lynch DA, Colby TV, Galvin JR, Brown KK, Chung MP, Cordier JF, du Bois RM, Flaherty KR, Franks TJ, Hansell DM, Hartman TE, Kazerooni EA, Kim DS, Kitaichi M, Koyama T, Martinez FJ, Nagai S, Midthun DE, Muller NL, Nicholson AG, Raghu G, Selman M, Wells A: Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med 2008, 177:1338-1347.
• [54]Leslie KO, Cool CD, Sporn TA, Curran-Everett D, Steele MP, Brown KK, Wahidi MM, Schwartz DA: Familial idiopathic interstitial pneumonia: histopathology and survival in 30 patients. Arch Pathol Lab Med 2012, 136:1366-1376.
• [55]Enomoto N, Suda T, Kato M, Kaida Y, Nakamura Y, Imokawa S, Ida M, Chida K: Quantitative analysis of fibroblastic foci in usual interstitial pneumonia. Chest 2006, 130:22-29.
• [56]King TE Jr, Schwarz MI, Brown K, Tooze JA, Colby TV, Waldron JA Jr, Flint A, Thurlbeck W, Cherniack RM: Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med 2001, 164:1025-1032.
• [57]Lee SH, Shim HS, Cho SH, Kim SY, Lee SK, Son JY, Jung JY, Kim EY, Lim JE, Lee KJ, Park BH, Kang YA, Kim YS, Kim SK, Chang J, Park MS: Prognostic factors for idiopathic pulmonary fibrosis: clinical, physiologic, pathologic, and molecular aspects. Sarcoidosis Vasc Diffuse Lung Dis 2011, 28:102-112.
• [58]Tiitto L, Bloigu R, Heiskanen U, Pääkkö P, Kinnula VL, Kaarteenaho-Wiik R: Relationship between histopathological features and the course of idiopathic pulmonary fibrosis/usual interstitial pneumonia. Thorax 2006, 61:1091-1095.
• [59]Flaherty KR, Colby TV, Travis WD, Toews GB, Mumford J, Murray S, Thannickal VJ, Kazerooni EA, Gross BH, Lynch JP 3rd, Martinez FJ: Fibroblast foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am J Respir Crit Care Med 2003, 167(10):1410-5.
• [60]Hanak V: Ryu JH, de CE, Limper AH, Hartman TE, Decker PA, Myers JL: Profusion of fibroblast foci in patients with idiopathic pulmonary fibrosis does not predict outcome. Respir Med 2008, 102:852-856.
• [61]Kaarteenaho-Wiik R, Tani T, Sormunen R, Soini Y, Virtanen I, Pääkkö P: Tenascin immunoreactivity as a prognostic marker in usual interstitial pneumonia. Am J Respir Crit Care Med 1996, 154:511-518.
• [62]Berbescu EA, Katzenstein AL, Snow JL, Zisman DA: Transbronchial biopsy in usual interstitial pneumonia. Chest 2006, 129:1126-1131.
• [63]Tomassetti S, Cavazza A, Colby TV, Ryu JH, Nanni O, Scarpi E, Tantalocco P, Buccioli M, Dubini A, Piciucchi S, Ravaglia C, Gurioli C, Casoni GL, Gurioli C, Romagnoli M, Poletti V: Transbronchial biopsy is useful in predicting UIP pattern. Respir Res 2012, 13:96. BioMed Central Full Text
• [64]Shim HS, Park MS, Park IK: Histopathologic findings of transbronchial biopsy in usual interstitial pneumonia. Pathol Int 2010, 60:373-377.
• [65]Katzenstein AL: Smoking-related interstitial fibrosis (SRIF), pathogenesis and treatment of usual interstitial pneumonia (UIP), and transbronchial biopsy in UIP. Mod Pathol 2012, 25(Suppl 1):S68-S78.
• [66]Babiak A, Hetzel J, Krishna G, Fritz P, Moeller P, Balli T, Hetzel M: Transbronchial cryobiopsy: a new tool for lung biopsies. Respiration 2009, 78:203-208.
• [67]Casoni GL, Cavazza A, Dubini A, Tomassetti S, Romagnoli M, Ravaglia C, Gurioli C, Pietrangeli C, Poletti V: Identification of the pathological pattern by transbronchial lung cryobiopsies in patients with fibrosing diffuse parenchymal lung disease. Eur Respir J 2012, 40(Suppl 56):512. Abstract
• [68]Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ: Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012, 366:1968-1977.
• [69]Meyer KC, Raghu G, Baughman RP, Brown KK, Costabel U, du Bois RM, Drent M, Haslam PL, Kim DS, Nagai S, Rottoli P, Saltini C, Selman M, Strange C, Wood B: An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 2012, 185:1004-1014.
• [70]Karvonen HM, Lehtonen ST, Sormunen RT, Harju TH, Lappi-Blanco E, Bloigu RS, Kaarteenaho RL: Myofibroblasts in interstitial lung diseases show diverse electron microscopic and invasive features. Lab Invest 2012, 92:1270-1284.
• [71]Larsen BT, Colby TV: Update for pathologists on idiopathic interstitial pneumonias. Arch Pathol Lab Med 2012, 136:1234-1241.
• [72]Ryerson CJ, Urbania TH, Richeldi L, Mooney JJ, Lee JS, Jones KD, Elicker BM, Koth LL, King TE Jr, Wolters PJ, Collard HR: Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J 2012. Dec 6. (epub ahead of print)